-
A ranar 21 ga Maris, 2025, Junshi Biosciences ta sanar da cewa Hukumar Kayayyakin Lafiya ta Kasa ("NMPA") ta amince da ƙarin amfani da sabon magani ("sNDA") don samfurin kamfanin, toripalimab, tare da haɗin gwiwa da bevacizumab don maganin farko na marasa lafiya da ba za a iya cirewa ba ko kuma waɗanda suka kamu da cutar...Kara karantawa»
-
A ranar 21 ga Maris, 2025, ta sanar da cewa an ba da izinin amfani da sabon magani ("NDA") don TAZVERIK® (tazemetostat) a China don maganin manya da suka sake komawa ko suka sake yin rashin lafiya ("R/R") tare da maye gurbin EZH2 waɗanda suka sami aƙalla biyu a baya ...Kara karantawa»
-
A ranar 10 ga Maris, 2025, Sichuan Kelun-Biotech ta sanar da cewa Hukumar Kayayyakin Lafiya ta Kasa (NMPA) ta amince da maganin antigen 2 (TROP2) mai sarrafa maganin antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT, wanda a da ake kira SKB264/MK-2870) don tallatawa don amfanin jama'a...Kara karantawa»
-
A ranar 18 ga Maris, 2025, Alphamab Oncology ta sanar da cewa Cibiyar Kimanta Magunguna (CDE) ta Hukumar Kayayyakin Lafiya ta Kasa (NMPA) ta ba da izinin ba da takardar shaidar maganin cutar HER2 biparatopic antibody-drug conjugate (ADC) JSKN003. An ba da takardar shaidar maganin cutar ne don ...Kara karantawa»
-
A ranar 10 ga Maris, 2025, Hansoh Pharma ta sanar da cewa Hukumar Kula da Kayayyakin Lafiya ta Kasa ta China (“NMPA”) ta amince da amfani da Sabbin Magunguna na uku ("NDA") na sabuwar maganin Ameile (阿美乐®) na kungiyar (Aumolertinib Mesilate Tablets) don maganin marasa lafiya da suka kamu da cutar...Kara karantawa»
-
A ranar 12 ga Maris, 2025, Kamfanin Zai Lab Limited ya sanar da cewa Hukumar Kula da Kayayyakin Lafiya ta Kasa (NMPA) ta kasar Sin ta amince da neman lasisin Biologics (BLA) don maganin TIVDAK (tisotumab vedotin-tftv) ga marasa lafiya da ke fama da cutar kansar mahaifa mai sake dawowa ko kuma ta yaɗuwa, wadanda ke fama da cutar...Kara karantawa»
-
A ranar 5 ga Maris, 2025, Ascentage Pharma ta sanar da cewa Cibiyar Kimanta Magunguna (CDE) ta Hukumar Kayayyakin Lafiya ta Kasa (NMPA) ta ba da izinin maganinta, olverembatinib, a matsayin Naɗin Magani na Musamman (BTD), don haɗa shi da maganin chemotherapy mai ƙarancin ƙarfi a karon farko...Kara karantawa»
-
A ranar 4 ga Maris, 2025, BeiGene ta sanar da cewa Hukumar Abinci da Magunguna ta Amurka (FDA) ta amince da TEVIMBRA (tislelizumab-jsgr), tare da maganin chemotherapy mai ɗauke da platinum, don maganin farko ga manya da ke fama da cutar kansar squamous cell carcinoma (ESCC) wanda ba a iya cirewa ko kuma wanda ya kamu da cutar kansar esophageal ...Kara karantawa»
-
A ranar 25 ga Fabrairu, 2025, Hukumar Kula da Kayayyakin Lafiya ta Kasa ta kasar Sin (NMPA) ta amince da amfani da finotonlimab tare da SCT510 don maganin cutar kansar hanta wadda ba za a iya cirewa ba ko kuma wadda ba a taba yi mata magani a baya ba. Finotonlimab wani nau'in IgG4 ne da aka sake hada shi da dan adam...Kara karantawa»
-
A ranar 8 ga Fabrairu, 2025, Hukumar Kula da Kayayyakin Lafiya ta Kasa (NMPA) ta kasar Sin ta amince da finotonlimab na Sinocelltech Group Ltd, wani maganin rigakafi na monoclonal monoclonal 1 (PD-1) wanda aka tsara don mutuwa 1 (PD-1), don amfani tare da maganin chemotherapy na tushen platinum a matsayin magani na farko don sake dawowa da/ko metastases...Kara karantawa»
-
A ranar 21 ga Fabrairu, 2025, Cibiyar Kimanta Magunguna (CDE) ta Hukumar Kayayyakin Lafiya ta Kasa (NMPA) ta ba da izinin Nadin Breakthrough Therapy (BTD) don Satri-cel (CT041) (wani samfurin ƙwayoyin T-cell na CAR da ke da alaƙa da Claudin18.2), don ci gaba da cutar ciki/esophagogastric june...Kara karantawa»
-
A ranar 22 ga Fabrairu, 2025, Cibiyar Kimanta Magunguna (CDE) ta Hukumar Kayayyakin Lafiya ta Kasa (NMPA) ta amince da Amfani da Sabbin Magani (NDA) don allurar ipilimumab (anti-CTLA-4 monoclonal antibody; Lambar R&D: IBI310) kuma an ba ta izinin yin bita na Fifiko a cikin com...Kara karantawa»
Cibiyar likitanci ta haɗin gwiwa ta Asibitin Ciwon Daji na Beijing